OB/GYN Clinical Alert – May 1, 2012
May 1, 2012
View Issues
-
Estrogen and Breast Cancer
Subjects in the Women's Health Initiative (WHI) trial estrogen-only study randomized to receive conjugated estrogens had a lower incidence of invasive breast cancer than did those who received placebo. -
Sentinel-Node Biopsy in Endometrial Cancer: Valid Approach?
Previous studies have demonstrated the feasibility of identifying sentinel lymph nodes (SLN) in the pelvic and para-aortic nodal basins in women with endometrial cancer. -
What the Internet Says about Pelvic Organ Prolapse and Urinary Incontinence
These authors from Louisiana State University and the University of Hawaii set out to evaluate the quality of information available on the Internet regarding pelvic organ prolapse and urinary incontinence. -
Special Feature: Fetal DNA Testing for Aneuploidy Detection
Currently, screening for fetal aneuploidy involves a variety of first-line methods that put into play combinations of maternal serum analytes and ultrasound exams in the first and second trimester, with invasive procedures such as chorionic villus sampling (CVS) and amniocentesis being reserved for those at higher risk by history, age, or worrisome results from first-line screening. As will be discussed, each screening combination comes with its own predictive accuracy and now patients and providers can choose from a buffet of screening options, including going right to the main course (amniocentesis or CVS) if one wants 100% accuracy at a small risk of fetal loss (we quote a 1 in 400 risk with amniocentesis and about a 1 in 100 risk for CVS). -
Pharmacology Watch: Does Aspirin Prevent Cancer?
In this issue: Aspirin and cancer prevention; rivaroxaban for pulmonary embolism; new rhinosinusitis practice guidelines; and FDA actions. -
Clinical Briefs in Primary Care supplement